Symantha Melemed

Symantha Melemed, PhD has extensive work experience in the pharmaceutical industry, focusing primarily on oncology. Symantha currently holds the position of Sr Vice President- Development at G1 Therapeutics, Inc. since March 2023. Prior to this, they served as Vice President, Clinical Development at the same company starting in April 2022.

Before joining G1 Therapeutics, Inc., Symantha worked at AbbVie as the Global Asset Strategy Leader, Oncology from June 2020 to April 2022. Prior to AbbVie, they held multiple roles at Eli Lilly and Company over a span of 16 years. Symantha'sroles included Global Product Team and Novel Target Leader- Oncology from June 2016 to June 2020, Senior Director- Oncology Tailoring from December 2014 to May 2016, Director- Oncology Patient Tailoring, Medical from December 2012 to November 2014, Clinical Research Scientist from July 2009 to December 2012, and Oncology Medical from September 2006 to July 2009.

Symantha Melemed, PhD, began their education in 1996 at Colorado State University, where they obtained their Bachelor of Science degree in Equine Science in the year 2000. Symantha then pursued their doctoral studies at Iowa State University from 2000 to 2004, specializing in Molecular Genetics. After completing their Ph.D., they furthered their education at the Indiana University School of Medicine from 2005 to 2006, where they pursued an NIH Fellowship in the field of Cancer Genetics and Cell Signaling.